Table 2.
Unadjusted and multivariate estimates of acute coronary syndrome risk with ‘low’ and ‘high’ doses of celecoxib and rofecoxib
| Characteristics | Cases, n = 328 n (%) | Controls, n = 478 n (%) | Crude OR | 95% CI (OR) | Adjusted OR | 95% CI Patient (OR) |
|---|---|---|---|---|---|---|
| Of those who could recall dose | ||||||
| NSAID use in the week before being in hospital | ||||||
| None (reference) | 256 (78.0) | 352 (73.6) | 1.00 | |||
| ‘Low’ dose of celecoxib/rofecoxib* | 8 (2.4) | 26 (5.4) | 0.42 | (0.19, 0.95) | 0.44 | (0.19, 1.03) |
| ’High’ dose of celecoxib/rofecoxib* | 30 (9.2) | 29 (6.1) | 1.42 | (0.83, 2.43) | 1.22 | (0.67, 2.21) |
| Other NSAIDs | 34 (10.4) | 71 (14.9) | 0.66 | (0.42, 1.02) | 0.67 | (0.41, 1.08) |
Adjustment was made for age, gender, hypertension, elevated cholesterol, current smoking status, aspirin use and antiplatelet drug use in the logistic regression model.
*
’Low’ dose users of celecoxib or rofecoxib ingested less than the median dose in the week before hospitalization; ‘high’ dose users ingested the median or higher. Median doses: celecoxib 1400 mg week−1; rofecoxib 93.75 mg week−1.